Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05176223 · ClinicalTrials.gov registry record · Phase 2

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

A Phase 2 study of Advanced Hepatocellular Carcinoma and Stage III Hepatocellular Carcinoma AJCC v8, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target
1
Study location

NCT05176223 is a Phase 2 study of Advanced Hepatocellular Carcinoma and Stage III Hepatocellular Carcinoma AJCC v8 that has completed, run by Mayo Clinic. The registered enrollment target is 29 participants, below the 86-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05176223, a Phase 2 study of Advanced Hepatocellular Carcinoma and Stage III Hepatocellular Carcinoma AJCC v8, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on the surface of liver cancer cells. The radioactive chemical compound (68Ga-PSMA) has been designed to circulate through the body and attach itself to the PSMA protein on liver cancer cells. A PET scan is then used to detect the location of the tumor cells. 68Ga-PSMA PET may improve upon the diagnosis and management of liver cancer.

Conditions Studied

Advanced Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Unresectable Hepatocellular Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • DRUG Gallium Ga 68 Gozetotide

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2022-01-30
Est. Completion 2025-12-31
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05176223

The ClinicalTrials.gov registry entry for NCT05176223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (66% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.

NCT05176223 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05176223 about?

NCT05176223 is a clinical study titled "68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer". This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on th...

What is the current status of trial NCT05176223?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2022-01-30. Estimated completion is 2025-12-31.

What conditions does trial NCT05176223 study?

This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma.

What interventions are being tested in trial NCT05176223?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Gallium Ga 68 Gozetotide (DRUG).

Who is sponsoring clinical trial NCT05176223?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05176223 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Hepatocellular Carcinoma

All registered trials for this condition

Stage III Hepatocellular Carcinoma AJCC v8

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.